Study on the Molecular Mechanism of Pleurotus Ostreatus-Zedoary Combination in the Treatment of Pancreatic Cancer Based on Network Pharmacology

Abstract

Abstract: Objective To explore the molecular mechanism of pleurotus ostreatus-zedoary turmeric combination in the treatment of pancreatic cancer by means of network pharmacology. Methods The main active components and action targets of pleurotus ostreatus-zedoary were obtained by TCMSP database, the pancreatic cancer related targets were obtained by OMIM, TTD, GeneCards and other databases, the intersection targets of traditional Chinese medicine and disease were obtained, and the protein interaction network (PPI) was analyzed by String database, and the core targets were screened. Finally, the ClueGO plug-in of Cytoscape3.7.2 software is used to analyze the enrichment of intersection targets by GO and KEGG, and a visual network of active components-target-signal pathway of traditional Chinese medicine is constructed. Results Six active components of pleurotus ostreatus-zedoary in the treatment of pancreatic cancer were obtained and 10 core targets,enrichment analysis mainly involved in biological processes and 4 mainly regulated signaling pathways in cancer. Conclusion The research based on network pharmacology shows that pleurotus ostreatus-zedoary can play a role in the treatment of pancreatic cancer through active components such as β-sitosterol and regulating PI3K-Akt signaling pathway, indicating that traditional Chinese medicine has the characteristics of multi-components, multi-targets and multi-pathways, and has a certain value in clinical application.

Key words: network pharmacology, pleurotus ostreatus, zedoary, pancreatic cancer, targe, pathway, molecular mechanism

CLC Number:

R285.5

HUA Wen, YANG Shi-yu, CHEN Mu-wen, WANG Yi-yi, CHEN Jun. Study on the Molecular Mechanism of Pleurotus Ostreatus-Zedoary Combination in the Treatment of Pancreatic Cancer Based on Network Pharmacology[J]. ZHONGHUA YANGSHENG BAOJIAN, 2025, 43(5): 92-96.

References

[1] 徐冬,杨飞,夏存冰.胰腺癌免疫治疗的应用现状与展望[J].中国肿瘤外科杂志,2023,15(1):85-91.
[2] HESSMANN E, SCHNEIDER G.New insights into pancreatic cancer: Notes from a virtual meeting[J].Gastroenterology,2021,161(3):785-791.
[3] MIZRAHI J D, SURANA R, VALLE J W, et al.Pancreatic cancer[J].Lancet,2020,395:2008-2020.
[4] CAI J, CHEN H, LU M, et al.Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis[J].Cancer Lett,2021,520:1-11.
[5] KOLTAI T, RESHKIN S J, CARVALHO T M A, et al. Resistance to gemcitabine in pancreatic ductal adenocarcinoma: A physiopathologic and pharmacologic review[J].Cancers (Basel),2022,14(10):2486.
[6] 陈诗,赵玥,王振,等.山慈菇药理作用及临床应用研究进展[J].中华中医药学刊,2023,41(6):247-250.
[7] 魏巍,王冰瑶.莪术及其主要成分的药理作用研究进展[J].药物评价研究,2022,45(10):2154-2160.
[8] 王宏伟,田欣圆,于蕾.山慈菇的化学成分及其抗肿瘤作用机制研究进展[J].内蒙古医科大学学报,2022,44(3):305-309.
[9] 杜星锴,何俊,王宇.莪术抗肿瘤活性成分的网络药理学研究[J].华西药学杂志,2022,37(3):257-262.
[10] RU J, LI P, WANG J, et al.TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J].J Cheminform,2014,6:13.
[11] KIM S, CHEN J, CHENG T, et al.PubChem 2019 update: improved access to chemical data[J].Nucleic Acids Res,2019,47(D1):D1102-D1109.
[12] DAINA A, MICHIELIN O, ZOETE V.SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules[J].Nucleic Acids Res,2019,47(W1):W357-W364.
[13] UNIPROT CONSORTIUM T.UniProt: the universal protein knowledgebase[J].Nucleic Acids Res,2018,46(5):2699.
[14] STELZER G, ROSEN N, PLASCHKES I, et al.The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses[J].Curr Protoc Bioinformatics,2016,54:1301-13033.
[15] AMBERGER J S, BOCCHINI C A, SCHIETTECATTE F, et al.OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders[J].Nucleic Acids Res,2015,43(Database issue):D789-D798.
[16] WANG Y, ZHANG S, LI F, et al.Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics[J].Nucleic Acids Res,2020,48(D1):D1031-D1041.
[17] SZKLARCZYK D, MORRIS J H, COOK H, et al.The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible[J].Nucleic Acids Res,2017,45(D1):D362-D368.
[18] 姜玲,高马欣瑶,陈涛,等.中医药治疗胰腺癌机制研究进展[J].辽宁中医药大学学报,2023,25(4):59-63.
[19] 余思敏,唐人彦,张秀梅,等.刘鲁明治疗胰腺癌腹水处方策略[J].中华中医药杂志,2022,37(7):3881-3884.
[20] 张依婷,沈敏鹤,阮善明.沈敏鹤治疗胰腺癌经验浅析[J].浙江中医药大学学报,2022,46(1):82-85.
[21] 陈月,邓宏,黄杰,等.刘伟胜教授辨治胰腺癌临证思路[J].天津中医药,2021,38(2):180-184.
[22] 谭栋,郑康,梁刚,等.慈丹胶囊联合mFOLFOX6方案治疗Bismuth-Corlette Ⅱ型肝门部胆管癌的临床研究[J].现代药物与临床,2019,34(4):1084-1089.
[23] HERBERTS C, MURTHA A J, FU S, et al.Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer[J].Eur Urol,2020,78(6):834-844.
[24] WU S, ZHANG Q, ZHANG F, et al.HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity[J].Nat Cell Biol,2019,21(8):1027-1040.
[25] YANG B, FENG X, LIU H, et al.High-metastatic cancer cells derived exosomal miR92a-3p promotes epithelial-mesenchymal transition and metastasis of low-metastatic cancer cells by regulating PTEN/Akt pathway in hepatocellular carcinoma[J].Oncogene,2020,39(42):6529-6543.
[26] LI N, YANG F, LIU D Y, et al.Scoparone inhibits pancreatic cancer through PI3K/Akt signaling pathway[J].World J Gastrointest Oncol,2021,13(9):1164-1183.
[27] 徐新生. 莪术溃坚方对胰腺癌抑瘤作用及其机理研究[D].天津:天津医科大学,2014.